Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Vaccination, Therapeutic, and Diagnostic Approaches for One Health
share announcement

Vaccination, Therapeutic, and Diagnostic Approaches for One Health

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 5627

Special Issue Editors

Dr. Nanda Kishore Routhu

E-Mail Website
Guest Editor
Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198-5800, USA
Interests: SARS-CoV-2; zoonosis; host-virus interaction
Dr. Sankar Renu

E-Mail Website
Guest Editor
Food Animal Health Research Program, The Ohio State University, Wooster, OH 44691, USA
Interests: nanoparticles; adjuvants; target delivery; veterinary vaccines; safety and vaccine efficacy; infectious diseases; zoonotic diseases; innate and adaptive immune response
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The One Health concept has been defined as “the integration effort of multiple disciplines working locally, nationally and globally to attaining optimal health for people, animals and the environment”. As one of the most hop and significant topic, One Health in action in response to the COVID-19 pandemic and other regional epidemics of zoonoses. All reaserches and authorities should engaged collaboratively with animal health veterinarians and epidemiologists to leverage disease outbreak knowledge, expertise and technical and support structures to stop the spread of infectious diseases and to develop novel vaccines, therapeutics, and diagnostics. The One Health approaches used, particularly shared responsibility and knowledge integration, are benefiting the management of this pandemic and future One Health global challenges.

Dr. Nanda Kishore Routhu
Dr. Sankar Renu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • one health
  • vaccine
  • therapeutics
  • diagnostics
  • antivirals
  • vaccination
  • zoonoses
  • animal health
  • veterinary
  • vaccines COVID-19

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

31 pages, 2964 KiB  
Article
Amphotericin B Nano-Assemblies Circumvent Intrinsic Toxicity and Ensure Superior Protection in Experimental Visceral Leishmaniasis with Feeble Toxic Manifestation
by Fauzia Jamal, Ishrat Altaf, Ghufran Ahmed, Sheikh Asad, Hira Ahmad, Qamar Zia, Asim Azhar, Saba Farheen, Taj Shafi, Shabana Karim, Swaleha Zubair and Mohammad Owais
Vaccines 2023, 11(1), 100; https://doi.org/10.3390/vaccines11010100 - 1 Jan 2023
Cited by 4 | Viewed by 2161
Abstract
In spite of its high effectiveness in the treatment of both leishmaniasis as well as a range of fungal infections, the free form of the polyene antibiotic amphotericin B (AmB) does not entertain the status of the most preferred drug of choice in [...] Read more.
In spite of its high effectiveness in the treatment of both leishmaniasis as well as a range of fungal infections, the free form of the polyene antibiotic amphotericin B (AmB) does not entertain the status of the most preferred drug of choice in clinical settings. The high intrinsic toxicity of the principal drug could be considered the main impedance in the frequent medicinal use of this otherwise very effective antimicrobial agent. Taking into consideration this fact, the pharma industry has introduced many novel dosage forms of AmB to alleviate its toxicity issues. However, the limited production, high cost, requirement for a strict cold chain, and need for parenteral administration are some of the limitations that explicitly compel professionals to look for the development of an alternate dosage form of this important drug. Considering the fact that the nano-size dimensions of drug formulation play an important role in increasing the efficacy of the core drug, we employed a green method for the development of nano-assemblies of AmB (AmB-NA). The as-synthesized AmB-NA manifests desirable pharmacokinetics in the treated animals. The possible mechanistic insight suggested that as-synthesized AmB-NA induces necrosis-mediated cell death and severe mitochondrial dysfunction in L. donovani promastigotes by triggering depolarization of mitochondrial membrane potential. In vivo studies demonstrate a noticeable decline in parasite burden in the spleen, liver, and bone marrow of the experimental BALB/c mice host. In addition to successfully suppressing the Leishmania donovani, the as-formed AmB-NA formulation also modulates the host immune system with predominant Th1 polarization, a key immune defender that facilitates the killing of the intracellular parasite. Full article
(This article belongs to the Special Issue Vaccination, Therapeutic, and Diagnostic Approaches for One Health)
►▼ Show Figures

Figure 1

20 pages, 4477 KiB  
Article
Design of a Multi-Epitope Vaccine against Tropheryma whipplei Using Immunoinformatics and Molecular Dynamics Simulation Techniques
by Thamer H. Albekairi, Abdulrahman Alshammari, Metab Alharbi, Amal F. Alshammary, Muhammad Tahir ul Qamar, Tasneem Anwar, Saba Ismail, Bilal Shaker and Sajjad Ahmad
Vaccines 2022, 10(5), 691; https://doi.org/10.3390/vaccines10050691 - 28 Apr 2022
Cited by 17 | Viewed by 3028
Abstract
Whipple’s disease is caused by T. whipplei, a Gram-positive pathogenic bacterium. It is considered a persistent infection affecting various organs, more likely to infect males. There is currently no licensed vaccination available for Whipple’s disease; thus, the development of a chimeric peptide-based [...] Read more.
Whipple’s disease is caused by T. whipplei, a Gram-positive pathogenic bacterium. It is considered a persistent infection affecting various organs, more likely to infect males. There is currently no licensed vaccination available for Whipple’s disease; thus, the development of a chimeric peptide-based vaccine against T. whipplei has the potential to be tremendously beneficial in preventing Whipple’s disease in the future. The present study aimed to apply modern computational approaches to generate a multi-epitope-based vaccine that expresses antigenic determinants prioritized from the core proteome of two T. whipplei whole proteomes. Using an integrated computational approach, four immunodominant epitopes were found from two extracellular proteins. Combined, these epitopes covered 89.03% of the global population. The shortlisted epitopes exhibited a strong binding affinity for the B- and T-cell reference set of alleles, high antigenicity score, nonallergenic nature, high solubility, nontoxicity, and excellent binders of DRB1*0101. Through the use of appropriate linkers and adjuvation with a suitable adjuvant molecule, the epitopes were designed into a chimeric vaccine. An adjuvant was linked to the connected epitopes to boost immunogenicity and efficiently engage both innate and adaptive immunity. The physiochemical properties of the vaccine were observed favorable, leading toward the 3D modeling of the construct. Furthermore, the vaccine’s binding confirmation to the TLR-4 critical innate immune receptor was also determined using molecular docking and molecular dynamics (MD) simulations, which shows that the vaccine has a strong binding affinity for TLR4 (−29.4452 kcal/mol in MM-GBSA and −42.3229 kcal/mol in MM-PBSA). Overall, the vaccine described here has a promising potential for eliciting protective and targeted immunogenicity, subject to further experimental testing. Full article
(This article belongs to the Special Issue Vaccination, Therapeutic, and Diagnostic Approaches for One Health)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop